A stopping rule for standard chemotherapy for metastatic breast cancer: lessons from a survey of Maryland medical oncologists. Cancer Invest. 1994; 12 (5):451–455.Benner SE, Fetting JH, Brenner MH. A stopping rule for standard chemo- therapy for metastatic breast cancer: lessons from a ...
Latest Conference Coverage Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers Mitazalimab Plus mFOLFIRINOX Improves Survival in Pancreatic Cancer Novel ADC Shows Promise in Platinum-Resistant Ovarian Cancer Chemo Should be Tailored to Decrease Neuropathy in Black Patients View More Latest...
Ritu Salani, MD, highlights data from the RUBY trial supporting the FDA approval of dostarlimab/chemotherapy for primary advanced endometrial cancer. Ultra-Hypofractionated RT Shows Control, Tolerability in Elderly Breast Cancer Russ Conroy October 17th 2024 ...
For patients with triple negative breast cancer, commonly these are anthracycline/taxane-based regimens. We did see some data at ESMO, the GeparOcto study, in which patients had different sequencing of chemotherapies, and this really didn’t ultimately change therapy. In this particular study, ...
Chemoradiotherapy with 5-fluorouracil (5-FU) and mitomycin-C is currently the standard treatment for anal cancer. Squamous cell carcinoma of the anal canal has historically been treated with abdominoperineal resection, but chemoradiation has been shown to result in high rates of local control and ...
Using chemotherapeutics as a strategy to kill cancer cells is like using a bomb to fight terrorist living amongst innocent civilians. As you can imagine, this strategy produces immense collateral damage. Why do chemotherapies fail? Fundamentally cancer is thought to be directly related to mutations ...
Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast Cancer Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer ...
Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researche...
Comparitive study of quality of life in locally advanced head and neck cancers with concurrent chemoradiotherpy with three weekly cisplatin versus weekly c... Background: Chemotherapy-induced amenorrhea (CIA) is one of the most frequent therapy-related adverse events observed in breast cancer patient...
How I currently approach therapeutic sequencing of bladder cancer has really evolved over the past few years. For many years, cisplatin-based chemotherapies were SOC. If patients were eligible for cisplatin, that’s what they would get; if not, [they would receive] carbopl...